首页> 外文期刊>Case Reports in Critical Care >Treatment of Severe Hypercapnic Respiratory Failure Caused by SARS-CoV-2 Lung Injury with ECCO 2 R Using the Hemolung Respiratory Assist System
【24h】

Treatment of Severe Hypercapnic Respiratory Failure Caused by SARS-CoV-2 Lung Injury with ECCO 2 R Using the Hemolung Respiratory Assist System

机译:使用血栓呼吸系统辅助系统治疗SARS-COV-2肺损伤引起的严重高态呼吸衰竭

获取原文
       

摘要

Acute respiratory distress syndrome (ARDS) due to COVID-19 leads to a high rate of mortality in the intensive care unit (ICU). A lung-protective mechanical ventilation strategy using low tidal volumes is a cornerstone to management, but uncontrolled hypercapnia is a life-threatening consequence among severe cases. A mechanism to prevent progressive hypercapnia may offset hemodynamic instability among patients who develop hypercapnia. We present the case of a woman in her mid-60’s with severe acute hypercapnic respiratory failure secondary to COVID-19 pneumonia who was successfully treated with early implementation of lung-protective ventilation facilitated by extracorporeal carbon dioxide removal (ECCO 2 R). This patient’s multiple comorbid conditions included obesity, hypertension, type 2 diabetes mellitus, and hypercholesterolemia. On her fifth day of admission at the referring hospital, her worsening hypoxemia prompted endotracheal intubation during which she developed pneumothorax. She was transferred to our institution for advanced care where upon arrival, she had profound hypercapnia and respiratory acidosis. She met the criteria for treatment with an investigational ECCO 2 R device (Hemolung Respiratory Assist System) available through FDA Emergency Use Authorization. ECCO 2 R is similar to extracorporeal membrane oxygenation (ECMO) but operates at much lower blood flows (350–550?mL/min) through a smaller 15.5 French central venous catheter. Standard heparinization was provided intravenously to achieve appropriate levels of anticoagulation during ECCO 2 R therapy. Unlike ECMO, ECCO 2 R does not provide clinically meaningful oxygenation but is simpler to implement and manage. The use of ECCO 2 R successfully corrected and controlled the patient’s hypercapnia and acidosis and enabled meaningful reductions in ventilator tidal volumes, respiratory rates, and mean airway pressures. The patient was weaned from ECCO 2 R after 17 days and from mechanical ventilation 10 days later. With low tidal volume ventilation facilitated by expeditious implementation of ECCO 2 R, the patient survived to discharge despite her many risk factors for a poor outcome and an extended duration of invasive mechanical ventilation.
机译:由于Covid-19,急性呼吸窘迫综合征(ARDS)导致重症监护单元(ICU)的死亡率高。使用低潮汐体积的肺保护机械通风策略是对管理的基石,但不受控制的Hypercapnia是严重案件之间的危及生命的后果。防止进步性高产腺炎的机制可以抵消发展Hypercapnia的患者的血液动力学不稳定。我们展示了60岁的女性的案例,其患有严重的急性高态性呼吸衰竭,继发于Covid-19肺炎,通过早期实施通过体外二氧化碳去除(ECCO 2 R)促进的肺保护通气促进的肺保护通气。该患者的多种合并条件包括肥胖,高血压,2型糖尿病,以及高胆固醇血症。在参考医院的第五天,她恶化的缺氧血症促使气管插管在其中开发了气胸。她被转移到我们的机构进行高级护理,在抵达时,她患有深厚的Hypercapnia和呼吸酸中毒。她符合通过FDA紧急使用授权的调查ECCO 2 R设备(Hemolung呼吸辅助系统)治疗标准。 ECCO 2 R类似于体外膜氧合(ECMO),但通过较小的15.5法法中央静脉导管,在更低的血液流(350-550×ml / min)下操作。静脉内提供标准肝素,以在ECCO 2 R治疗过程中达到适当水平的抗凝水平。与Ecmo不同,ECCO 2 R不提供临床有意义的氧合,但实施和管理更简单。 ECCO 2 R成功纠正并控制患者的患者的高曲线和酸中毒,并在呼吸机潮汐卷,呼吸率和平均气道压力方面实现了有意义的减少。在17天后并在10天后从机械通风后,患者从ECCO 2 R断奶。通过迅速实施ECCO 2 R促进的低潮量通风,患者幸存下来才能出院,尽管有许多危险因素,但令人难的结果和令人肠道机械通气的延长持续时间。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号